期刊文献+

脑血管病患者血浆PT、APTT、Fg变化及其临床意义 被引量:6

The change of PT,APTT and Fg in patients with cerebrovascular disease and its clinical significance
下载PDF
导出
摘要 目的探讨脑血管病血浆凝血酶原时间(PT)、活化部分凝血酶原时间(APTT)、纤维蛋白原(Fg)含量在脑血管病患者中的变化及其临床意义。方法选择脑血管病患者124例,对照组88例,采用凝固法、Clauss法分别检测血浆PT、APTT、Fg,分析其变化及临床意义。结果脑血管病患者血浆Fg含量明显高于对照组,差异有统计学意义(P<0.05);而PT、APTT含量与对照组比较差异无统计学意义(P>0.05)。结论 Fg含量对早期诊断脑血管病有重要的临床应用价值,而PT、APTT不能作为脑血管病的早期诊断指标。 Objective To investigate the change of PT and APTT and Fg in patients withcerebrovascular disease and its clinical significance.Methods Selected 124 patients with cerebrovascular disease as CVD group and 88 patients as control group and detected their plasma PT,and APTT by clot methods and Fg by clauss methods.Results The Fg level was significantly higherin CVD group than that in control group(P0.05).There were no significantlydifference in PT and APTT of CVD group and those of control group(P0.05).Conclusion Fgis of great clinical importance in earlydiagnosing cerebrovascular disease.While PT,APTT cannot be used as early diagnostic indicators.
出处 《中国实用医药》 2011年第21期35-36,共2页 China Practical Medicine
关键词 脑血管病 凝血酶原时间 活化部分凝血酶原时间 纤维蛋白原 Cerebrovascular disease PT APTT Fibrinogen
  • 相关文献

参考文献5

  • 1Tohgi H, Kawashima M, Tamura K, et al. Coagulation-fibrinolysis abnormalities in acute and chronicphases of cerebral thrombosis and embolis~ Storke, 1990,21 (12) : 1663-1667.
  • 2马付坚,黄承乐.急性脑梗塞患者的凝血、抗凝及纤溶状态评价[J].右江民族医学院学报,2000,22(4):525-527. 被引量:16
  • 3Cuomo O, Pignataro G, Gala R, et al. ische-mic volume, ameliorates neurologic deficits, and prolongs animal-survival in bothtransient and permanent focal ischemia.. Stroke, 2007,38 ( 12 ) :3272-3279.
  • 4张学勤,左大鹏,王秋萍,路阳,鞠淑英.急性脑卒中血浆纤溶状态的动态观察[J].中风与神经疾病杂志,1997,14(1):16-17. 被引量:37
  • 5Greenberg DA. Clinical Neurology. 5th cd. New york:McGraw Hill, 2002 : 283 -315.

二级参考文献8

  • 1赵海霞.组织型纤溶酶原激活物研究进展[J].国外医学(输血及血液学分册),1995,18(1):19-23. 被引量:21
  • 2TadadaA,TakadaY.Thephysiologicalaspectsoffibriolysis[J].ThrombRes,1994;76(1):1.[J].
  • 3RylattDB,BlakcAS,CottisLE.AnimmunoassayforhumanD-dimerusingmonoclonalantibodies[J].Thrombres,1983;31:767.
  • 4EritslandJ,SeljeflotI,ArnesenI,etal.Effectsoflongtermtreatmentwithwarfarinonfibrinogen,FPA,TATandD-dimerinpatientswithcoronaryarterydiseae[J].ThrombRes,1992;66:55.
  • 5AraiH,MiyakawaT,QzakikS,etal.ChangesofthelevelofantithrombinⅢpatientswithcerebrovasculardisease[J].ThrombRes,1983;3:197.
  • 6StrugerHAR,StietenP,HeijnerHFG,etal.Plassminogenactivator-1releadedplatelatplaysakeyroleinthrombosisresistance:studieswiththrombigeneratedinthechandleloop[J].ArteriosclerThromb,1994;14(8):1452
  • 7TakanoD,HaimingC.Markersofhypercoagulablestatefollowingacuteischmic[J].Stroke,1992;23:194.
  • 8FeinbergWM,BruckDC,RingME,etal.Hemostaticmarkersinacutestroke[J].Stroke,1989;20:592

共引文献51

同被引文献70

引证文献6

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部